Introduction
Malignant hyperthermia (MH) is a rare life-threatening response that
occurs in genetically susceptible individuals that triggered by exposure
to halogenated/volatile anesthetics commonly used during surgery
interventions, characterized by muscle rigidity, hyperthermia,
rhabdomyolysis, acidosis, tachycardia, and, if untreated, death(1).
Dantrolene is a well-known inhibitor of Ca2+ release
in skeletal muscle that has been used clinically as first-line therapy
for MH(2). A 14-year-old Chinese boy occurred fulminant MH after
cervical spine surgery even not exposed to volatile anesthetics or
succinylcholine and was successfully cured by combined treatment of
intravenous dantrolene, continuous veno-venous hemofiltration (CVVH),
and plasma exchange (PE) therapy. In this case, the pharmacokinetics of
intravenous dantrolene with CVVH/PE during fulminant malignant
hyperthermia were explored. We present the following case in accordance
with the CARE reporting checklist.